New pill takes on tough blood cancers in early trial

NCT ID NCT04775745

Recruiting now Disease control Sponsor: Newave Pharmaceutical Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study is testing an experimental oral drug called LP-168 in about 60 people with several types of B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to find the safest dose and to see how the drug behaves in the body. Researchers will also look for signs that the drug is shrinking tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LP-168 (an oral small molecule inhibitor)
What this could lead to: If it works, this could point toward a new treatment option for people with certain blood cancers that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 60 participants, so it is primarily testing safety and dosing. The drug may not work well or could have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma diffuse large B-cell lymphoma follicular lymphoma hairy cell leukemia Lymphoma, B-Cell, Marginal Zone mantle cell lymphoma marginal zone lymphoma Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLL / SLL DIFFUSE LARGE B-CELL LYMPHOMA FOLLICULAR LYMPHOMA HAIRY CELL LEUKEMIA MANTLE CELL LYMPHOMA MARGINAL ZONE LYMPHOMA WALDENSTROM MACROGLOBULINEMIA

Contacts and locations

Locations

Duke Univerisity
RECRUITING

Durham, North Carolina, 27708, United States
Huntsman Cancer Institute, University of Utah
RECRUITING

Salt Lake City, Utah, 84112, United States
Ohio State University
RECRUITING

Columbus, Ohio, 43210, United States
University of Cincinnati
RECRUITING

Cincinnati, Ohio, 45221, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.